• If you are wondering whether West Pharmaceutical Services is fairly priced or offering value right now, looking at a clear, structured view of its valuation can help you decide how it fits into your watchlist.
• The share price closed at US$248.95, with a 7.7% gain over the last 7 days, while the 1 year return sits at a 22.3% decline and the year to date return is a 9.9% decline.
• Over the past month, the stock recorded a 9.6% decline, and over 3 and 5 year periods the returns are 7.4% and 14.2% declines respectively. This gives useful context for anyone tracking price trends and can influence how investors think about risk, sentiment and what they are willing to pay for the shares today.
• On our 6 point undervaluation checklist, West Pharmaceutical Services currently scores 2 out of 6, which means some measures suggest value while others do not. Next, we will walk through the key valuation approaches behind that score, then finish with a way to assess valuation that goes beyond a single number.

West Pharmaceutical Services scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: West Pharmaceutical Services Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of a company’s future cash flows and discounts them back to today’s dollars, aiming to show what those future streams might be worth right now.

For West Pharmaceutical Services, the latest twelve month Free Cash Flow (FCF) is about $336.7 million. The model used here is a 2 Stage Free Cash Flow to Equity approach, which starts with explicit projections and then transitions into more mature assumptions. Analysts provide estimates up to 2026, where FCF is projected at $453.0 million, and Simply Wall St extrapolates further out to 2035, with discounted annual FCF figures ranging roughly from $420.3 million to $340.8 million over that period.

Putting those cash flows together, the DCF model arrives at an estimated intrinsic value of $166.39 per share, compared with the recent share price of $248.95. That implies the stock is about 49.6% overvalued on this model.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests West Pharmaceutical Services may be overvalued by 49.6%. Discover 52 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: West Pharmaceutical Services Price vs Earnings

For a profitable company like West Pharmaceutical Services, the P/E ratio is a useful way to relate what you pay per share to the earnings the business is currently generating. Investors typically accept a higher P/E when they expect stronger growth or lower perceived risk, and a lower P/E when they see weaker growth or higher risk.

West Pharmaceutical Services is trading on a P/E of 36.4x. That is close to the Life Sciences industry average P/E of 36.5x, but higher than the peer group average of 27.7x. On the surface, that suggests the market is currently willing to pay more for each dollar of West Pharmaceutical Services’ earnings than for many peers.

Simply Wall St’s Fair Ratio for West Pharmaceutical Services is 24.9x. This proprietary figure reflects factors such as earnings growth, industry, profit margins, market cap and company specific risks in one number, which can be more tailored than a simple comparison with peers or the broad industry. Comparing the current 36.4x P/E with the 24.9x Fair Ratio indicates the shares are pricing in a richer valuation than this model implies.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 22 top founder-led companies.

Upgrade Your Decision Making: Choose your West Pharmaceutical Services Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple way for you to tell the story behind your numbers by pairing your view of a company with your own fair value, revenue, earnings and margin assumptions.

A Narrative links what you believe about a business, such as West Pharmaceutical Services’ market position or pricing power, to a specific financial forecast and then to a fair value that you can compare with today’s share price.

On Simply Wall St’s Community page, millions of investors use Narratives as an easy tool to see whether their fair value is above or below the current price, which can help them decide if a stock looks attractive, expensive or worth watching.

Because Narratives update automatically when new information such as earnings releases or major news is added to the platform, your story and fair value stay current without you having to rebuild your analysis each time.

For example, one West Pharmaceutical Services Narrative on the Community page might assume a relatively high fair value based on stronger revenue and margin expectations, while another might set a lower fair value using more conservative forecasts and a higher discount rate.

Do you think there's more to the story for West Pharmaceutical Services? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.